Trial Profile
Improving Quality of Life and Social Functionality With Escitalopram in the Treatment of Major Depressive Disorder With Anxiety Symptom
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Escitalopram (Primary)
- Indications Anxiety disorders; Major depressive disorder
- Focus Therapeutic Use
- Sponsors Xian-Janssen
- 01 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 05 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 25 Jan 2015 Planned End Date changed from 1 Aug 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.